Anbio Biotechnology — Revenue by Fiscal Year
4 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/387e9dcc-0e16-4145-b441-7fda22015808/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $8.6M | 2025-01-01 – 2025-12-31 | evidence 0001185185-26-001294 |
| FY 2024 | $8.2M | 2024-01-01 – 2024-12-31 | evidence 0001213900-25-035802 |
| FY 2023 | $6.7M | 2023-01-01 – 2023-12-31 | evidence 0001213900-25-035802 |
| FY 2022 | $23.5M | 2022-01-01 – 2022-12-31 | evidence 0001213900-25-035802 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Anbio Biotechnology — all facts · Net Income · Operating Income